CN110327471A - A kind of endoscopy spasmolysis defoaming agent and preparation method thereof - Google Patents
A kind of endoscopy spasmolysis defoaming agent and preparation method thereof Download PDFInfo
- Publication number
- CN110327471A CN110327471A CN201910677597.6A CN201910677597A CN110327471A CN 110327471 A CN110327471 A CN 110327471A CN 201910677597 A CN201910677597 A CN 201910677597A CN 110327471 A CN110327471 A CN 110327471A
- Authority
- CN
- China
- Prior art keywords
- defoaming agent
- endoscopy
- spasmolysis
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002518 antifoaming agent Substances 0.000 title claims abstract description 64
- 238000001839 endoscopy Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 239000006185 dispersion Substances 0.000 claims description 21
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 16
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 13
- 238000002604 ultrasonography Methods 0.000 claims description 10
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 7
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 7
- 239000001540 sodium lactate Substances 0.000 claims description 7
- 229940005581 sodium lactate Drugs 0.000 claims description 7
- 235000011088 sodium lactate Nutrition 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000004570 mortar (masonry) Substances 0.000 claims description 6
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- -1 polydimethylsiloxanes Polymers 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 239000000839 emulsion Substances 0.000 abstract description 10
- 239000006260 foam Substances 0.000 abstract description 8
- 238000002834 transmittance Methods 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000003254 anti-foaming effect Effects 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 description 13
- 239000012530 fluid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of endoscopy spasmolysis defoaming agent and preparation method thereof, the defoaming agent is made of the l-menthol of 1-3,0.5-1 parts of surfactant, 0.05-0.1 parts of defoaming agent and 65-75 parts of pure water, endoscopy spasmolysis defoaming agent provided by the invention can have extraordinary foam inhibition ability in gastrointestinal tract environment, antifoaming speed is fast, and light transmittance is significantly better than existing emulsion.
Description
Technical field
The invention belongs to endoscopy formulation art, in particular to a kind of endoscopy spasmolysis defoaming agent and its preparation.
Background technique
Medically the lesion situation in gastrointestinal tract is checked commonly using high definition scope, however mucus and foam in gastrointestinal tract
The visual field for usually influencing scope, leads to that minimal disease recall rate is low, the review time extends；Then the excess shrinkage of gastrointestinal tract also can
It prevents correctly to diagnose and can make the cancer site of small damage such as small size that can be missed.
In order to solve problem above present in endoscopic procedures, CN1893982A discloses a kind of containing menthol
Preparation, said preparation are emulsion, and containing l-menthol, surfactant and defoaming agent, said preparation is used to inhibit smooth muscle contraction,
And stability can be kept for a long time, shows high light transmittance.But antifoam content present in the emulsion is low, if
The content of defoaming agent is increased, the dissolubility of defoaming agent is reduced, can be precipitated from emulsion, and defoaming agent present in the emulsion is only
Bubble present in elimination emulsion use process, cannot eliminate existing bubble in gastric juice, clinically, better in order to reach
Defoaming effect, the emulsion also need in addition to be used together with defoaming agent, and defoaming effect is poor.
Summary of the invention
In order to solve the above technical problem, the present invention provides a kind of defoaming agents for being exclusively used in endoscopy, which can
To be used alone, while there is defoaming effect, also there is good light transmittance.
Specific technical solution of the present invention is as follows:
The present invention provides a kind of endoscopy spasmolysis defoaming agent, which includes each ingredient of following parts by weight:
L-menthol 1-3 surfactant 0.5-1
Defoaming component 0.05-0.1 pure water 65-75.
Further to improve, the defoaming component is 0.02-0.04 parts of sodium taurocholate and 0.03-0.06 parts of poly dimethyl
The mixture of siloxanes.
Further to improve, the sodium taurocholate and dimethyl silicone polymer form dispersion, the preparation side of the dispersion
Method are as follows: sodium taurocholate is placed in mortar, dimethyl silicone polymer is slowly added under grinding, grinds 20-30min, revolving speed is
500rmp reversely continues to grind 20-30min, revolving speed 500rmp, take out, cross 120 meshes, dispersion is made.
Further to improve, the surfactant includes each ingredient of following parts by weight:
Polyethylene glycol 1500 0.05-0.2 octadecyltrimethylammonium chloride 0.35-0.5
Sodium lactate 0.1-0.3.
Further to improve, the defoaming agent further includes the glycyrrhizin that parts by weight are 1-3 parts.
Another aspect of the present invention provides a kind of preparation method of endoscopy spasmolysis defoaming agent, which includes as follows
Step: surfactant being added in pure water, 7min is stirred at 500rmp, stands, l-menthol and defoaming component are added
Enter in above-mentioned solution, defoaming agent is made in ultrasound.
Preferably, the condition of the ultrasound are as follows: 15-20 DEG C, ultrasonic power 65-75w, ultrasonic time 3-5s, interval time
4-5s accumulates ultrasonic time 30-35min.
The present invention provides a kind of endoscopy spasmolysis defoaming agent, which has extraordinary suppression in gastrointestinal tract environment
Bubble ability, antifoaming speed is fast, and light transmittance is significantly better than existing emulsion and defoaming agent.
Specific embodiment
Embodiment 1
Embodiment 2
The sodium taurocholate and dimethyl silicone polymer form dispersion, the dispersion the preparation method comprises the following steps: by sodium taurocholate
It is placed in mortar, dimethyl silicone polymer is slowly added under grinding, grind 20min, revolving speed 500rmp reversely continues to grind
20min, revolving speed 500rmp take out, and cross 120 meshes, and dispersion is made.
Embodiment 3
The endoscopy spasmolysis defoaming agent the preparation method comprises the following steps:
Polyethylene glycol 1500, octadecyltrimethylammonium chloride and sodium lactate are added in pure water, stirred at 500rmp
7min to be mixed, is stood, l-menthol and sodium taurocholate and dimethyl silicone polymer are added in above-mentioned solution, defoaming agent is made in ultrasound,
The condition of ultrasound are as follows: 15 DEG C of ultrasonic temperature, ultrasonic power 65w, ultrasonic time 5s, interval time 4s, accumulate ultrasonic time
35min。
Embodiment 4
The sodium taurocholate and dimethyl silicone polymer form dispersion, the dispersion the preparation method comprises the following steps: by sodium taurocholate
It is placed in mortar, dimethyl silicone polymer is slowly added under grinding, grind 30min, revolving speed 500rmp reversely continues to grind
30min, revolving speed 500rmp take out, and cross 120 meshes, and dispersion is made.
The endoscopy spasmolysis defoaming agent the preparation method comprises the following steps:
Polyethylene glycol 1500, octadecyltrimethylammonium chloride and sodium lactate are added in pure water, stirred at 500rmp
7min is mixed, is stood, l-menthol and dispersion are added in above-mentioned solution, defoaming agent, ultrasonic condition is made in ultrasound are as follows: super
20 DEG C of sound temperature, ultrasonic power 75w, ultrasonic time 3s, interval time 4s, accumulate ultrasonic time 30min.
Embodiment 5
Embodiment 6
Embodiment 7
The endoscopy spasmolysis defoaming agent the preparation method comprises the following steps:
Polyethylene glycol 1500, octadecyltrimethylammonium chloride and sodium lactate are added in pure water, stirred at 500rmp
7min is mixed, is stood, l-menthol, sorbierite, polyacrylic acid, carbomer, sodium taurocholate and dimethyl silicone polymer are added above-mentioned
In solution, defoaming agent, ultrasonic condition is made in ultrasound are as follows: and 17 DEG C of ultrasonic temperature, ultrasonic power 70w, ultrasonic time 4s, interval
Time 5s accumulates ultrasonic time 35min.
Embodiment 8
The sodium taurocholate and dimethyl silicone polymer form dispersion, the dispersion the preparation method comprises the following steps: by sodium taurocholate
It is placed in mortar, dimethyl silicone polymer is slowly added under grinding, grind 30min, revolving speed 500rmp reversely continues to grind
30min, revolving speed 500rmp take out, and cross 120 meshes, and dispersion is made.
The endoscopy spasmolysis defoaming agent the preparation method comprises the following steps:
Polyethylene glycol 1500, octadecyltrimethylammonium chloride and sodium lactate are added in pure water, stirred at 500rmp
7min is mixed, is stood, l-menthol, sorbierite, polyacrylic acid, carbomer, dispersion are added in above-mentioned solution, ultrasound is made
Defoaming agent, ultrasonic condition are as follows: 16 DEG C of ultrasonic temperature, ultrasonic power 68w, ultrasonic time 4s, interval time 5s, when accumulation is ultrasonic
Between 35min.
Embodiment 9
The sodium taurocholate and dimethyl silicone polymer form dispersion, the dispersion the preparation method comprises the following steps: by sodium taurocholate
It is placed in mortar, dimethyl silicone polymer is slowly added under grinding, grind 30min, revolving speed 500rmp reversely continues to grind
30min, revolving speed 500rmp take out, and cross 120 meshes, and dispersion is made.
The endoscopy spasmolysis defoaming agent the preparation method comprises the following steps:
Polyethylene glycol 1500, octadecyltrimethylammonium chloride and sodium lactate are added in pure water, stirred at 500rmp
7min is mixed, is stood, l-menthol and dispersion and glycyrrhizin are added in above-mentioned solution, defoaming agent, ultrasonic item is made in ultrasound
Part are as follows: 20 DEG C of ultrasonic temperature, ultrasonic power 75w, ultrasonic time 3s, interval time 4s, accumulate ultrasonic time 30min.
Embodiment 10
Preparation method is the same as embodiment 9.
Embodiment 11
Preparation method is the same as embodiment 9.
Reference examples 1
Emulsion disclosed in the embodiment 1 of CN1893982A.
Reference examples 2
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 3.
Reference examples 3
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 3.
Reference examples 4
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 3.
Reference examples 5
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 3.
Reference examples 6
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 3.
Reference examples 7
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 5.
Reference examples 8
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 5.
Reference examples 9
The preparation method of endoscopy spasmolysis defoaming agent is the same as embodiment 5.
Reference examples 10
Preparation method is the same as embodiment 9.
Reference examples 11
Preparation method is the same as embodiment 9.
Reference examples 12
Preparation method is the same as embodiment 9.
The experiment of 1 defoaming capacity of experimental example
According to the method configuration simulated gastric fluid and simulated intestinal fluid in 2,010 2 annex XA of Chinese Pharmacopoeia:
Simulated gastric fluid: taking dilute hydrochloric acid 16.4mL, and water about 800mL and pepsin 10g is added to be diluted with water into after shaking up
1000mL to get.
Simulated intestinal fluid: i.e. phosphate buffer (containing pancreatin) (pH6.8).
30mL bottle is taken, is divided into four groups, first group and second group of each bottle and places simulated gastric fluid 10mL；Third group and
Four groups of each bottle places simulated intestinal fluid 10mL, and then first group and third group are put into the embodiment of the present invention and reference examples in 25 DEG C
The defoaming agent 10mL of offer, second group and the 4th group is put into the defoaming agent that the embodiment of the present invention and reference examples provide at 37 DEG C
10mL, each group keep temperature, vibrate 1min on oscillator (200r/min), after 1min, measure foam vanishing time T and light transmission
Rate Y, the results are shown in Table 1.
The defoaming capacity experimental result of each embodiment of table 1 and reference examples
As can be seen from the table, endoscopy spasmolysis defoaming agent provided by the invention is in simulated gastric fluid, simulated intestinal fluid, and
25 DEG C or 37 DEG C are detected, and light transmittance is significantly better than control group, and foam time is significantly lower than control group, and from control
The experimental data of example 1 can be seen that reference examples 1 offer emulsion pH be 7, and temperature be 25 DEG C when, with fine light transmission
Rate, and foam time is short, and in 37 DEG C or simulated gastric fluid, light transmittance is significantly lower than defoaming agent provided by the present application, and
Foam time significantly extends.And as can be seen from the above table, defoaming component significantly affects foam time, the significant shadow of surfactant
Ring light transmittance.
Obtain as a result, endoscopy spasmolysis defoaming agent provided by the invention for carry out gastrointestinal endoscopy when, Ke Yixian
It writes and improves gastrointestinal endoscopy light transmittance, and significantly shorten foam time.
2 adsorption experiment of experimental example
The protein solution for being 1.0mg/mL with phosphate buffer (pH6.8) configuration gastrointestinal tract protein concentration, incite somebody to action this respectively
Defoaming agent (microspheres amount 0.3g) addition for inventing the embodiment and reference examples that provide is placed in containing protein solution (0.3mL)
In test tube, (120r/min) 4h is vibrated in 37 DEG C of constant temperature oscillator, then measures protein content in solution.Before absorption
The amount of albumen calculates the protein adsorption quantity on microballoon, protein adsorption rate=(protein content after starting protein content -4h)/starting albumen afterwards
Amount * 100%, each group is shown in Table 2 to the adsorption rate of albumen.
The Adsorption experimental results of table 2 each embodiment and reference examples
| Sample | Adsorption rate (%) |
| Embodiment 7 | 45.6 |
| Reference examples 7 | 0 |
| Reference examples 8 | 2.3 |
| Reference examples 9 | 8.3 |
As can be seen from the table, defoaming agent provided by the invention has certain suction-operated to gastrointestinal tract albumen, thus
It can be concluded that defoaming agent provided by the invention can have the effect of certain adhesion protein, can will adhere in intestinal wall
In protein adsorption to defoaming agent, the clarity to gastrointestinal examination is further improved, improves the accuracy of inspection.
Experimental example 3 inhibits spasm experiment
SD rat, weight 200-250g, male；
Rat is divided into 6 groups, is respectively administered 1 group, is administered 2 groups, compares 1 group, 2 groups of control, control 3 groups and blank control
Group after fasting 12h, is administered as follows:
The defoaming agent 5mL of 1 group of gastric infusion embodiment of the present invention 1 is administered；
The defoaming agent 5mL of 2 groups of gastric infusion embodiment of the present invention 9 is administered；
Compare the defoaming agent 5mL of 1 group of gastric infusion reference examples 10 of the present invention；
Compare the defoaming agent 5mL of 2 groups of gastric infusions reference examples 11 of the present invention；
Compare the defoaming agent 5mL of 3 groups of gastric infusions reference examples 12 of the present invention；
Blank control group gives isometric physiological saline.
=(mean tension after being administered to mean tension one after KCl)/is calculated, inhibiting rate (%) using existing method (gives KCl
One rest tension of mean tension afterwards) × 100%, each group inhibiting rate the results are shown in Table 3.
The spasm inhibition assay result of 3 each group of table
| Group | Inhibiting rate (%) |
| Blank control group | 7.56±1.23 |
| It is administered 1 group | 65.94±2.37 |
| It is administered 2 groups | 90.68±5.66 |
| Compare 1 group | 22.38±2.82 |
| Compare 2 groups | 60.32±1.57 |
| Compare 3 groups | 61.55±2.96 |
As can be seen from the table, defoaming agent provided in an embodiment of the present invention there is significant inhibition to make the spasm of colon
With as can be seen from the table, glycyrrhizin and l-menthol have synergistic effect.
Claims (8)
1. a kind of endoscopy spasmolysis defoaming agent, which is characterized in that the defoaming agent includes each ingredient of following parts by weight:
L-menthol 1-3 surfactant 0.5-1
Defoaming component 0.05-0.1 pure water 65-75.
2. endoscopy spasmolysis defoaming agent as described in claim 1, which is characterized in that the defoaming component is 0.02-0.04
The sodium taurocholate of part and the mixture of 0.03-0.06 parts of dimethyl silicone polymer.
3. endoscopy spasmolysis defoaming agent as claimed in claim 2, which is characterized in that the sodium taurocholate and polydimethylsiloxanes
Alkane forms dispersion, the dispersion the preparation method comprises the following steps: sodium taurocholate is placed in mortar, be slowly added to poly dimethyl under grinding
Siloxanes grinds 20-30min, revolving speed 500rmp, reversely continues to grind 20-30min, revolving speed 500rmp, take out, crosses 120
Dispersion is made in mesh.
4. endoscopy spasmolysis defoaming agent as described in claim 1, which is characterized in that the surfactant includes following weight
Measure each ingredient of part:
Polyethylene glycol 1500 0.05-0.2 octadecyltrimethylammonium chloride 0.35-0.5 sodium lactate 0.1-0.3.
5. endoscopy spasmolysis defoaming agent as described in claim 1, which is characterized in that the defoaming agent further includes that parts by weight are
0.01-0.05 parts of sorbierite, 0.2-0.4 parts of polyacrylic acid and 0.7-1.2 parts of carbomer.
6. endoscopy spasmolysis defoaming agent as described in claim 1, which is characterized in that the defoaming agent further includes that parts by weight are
1-3 parts of glycyrrhizin.
7. a kind of preparation method of endoscopy spasmolysis defoaming agent described in claim 1, which is characterized in that the method includes
Following steps: surfactant being added in pure water, 7min is stirred at 500rmp, is stood, by l-menthol and defoaming group
Divide and be added in above-mentioned solution, defoaming agent is made in ultrasound.
8. preparation method as claimed in claim 7, which is characterized in that the condition of the ultrasound are as follows: 15-20 DEG C of ultrasonic temperature,
Ultrasonic power 65-75w, ultrasonic time 3-5s, interval time 4-5s accumulate ultrasonic time 30-35min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910070037 | 2019-01-24 | ||
| CN2019100700374 | 2019-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110327471A true CN110327471A (en) | 2019-10-15 |
| CN110327471B CN110327471B (en) | 2021-08-27 |
Family
ID=68147500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910677597.6A Active CN110327471B (en) | 2019-01-24 | 2019-07-25 | Antispasmodic agent for endoscopy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110327471B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893982A (en) * | 2003-06-30 | 2007-01-10 | 日本制药株式会社 | Menthol-containing preparation |
| US20070148099A1 (en) * | 2005-12-27 | 2007-06-28 | Burke Susan E | Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN106177971A (en) * | 2016-07-20 | 2016-12-07 | 贵州理工学院 | Potato starch capsule shells containing menthol |
-
2019
- 2019-07-25 CN CN201910677597.6A patent/CN110327471B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893982A (en) * | 2003-06-30 | 2007-01-10 | 日本制药株式会社 | Menthol-containing preparation |
| CN102038963A (en) * | 2003-06-30 | 2011-05-04 | 日本制药株式会社 | Method for preparing a stabilised menthol emulsion |
| US20070148099A1 (en) * | 2005-12-27 | 2007-06-28 | Burke Susan E | Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants |
| CN103110961A (en) * | 2012-11-30 | 2013-05-22 | 江苏唯德康医疗科技有限公司 | Preparation method of high-definition endoscope mucus-removal defoaming composite preparation |
| CN106177971A (en) * | 2016-07-20 | 2016-12-07 | 贵州理工学院 | Potato starch capsule shells containing menthol |
Non-Patent Citations (2)
| Title |
|---|
| H.-G. GRIGOLEIT ET AL: ""Pharmacology and preclinical pharmacokinetics of peppermint oil"", 《PHYTOMEDICINE》 * |
| 曾玉兰: ""多效内窥镜乳的制备及质量控制"", 《北方药学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110327471B (en) | 2021-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101322848B (en) | Composition for gastroscopy and preparation thereof | |
| WO2017202496A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae | |
| JP2001517708A (en) | Pharmaceutical composition for treating inflammatory bowel disease | |
| Marshall et al. | On Call Principles and Protocols E-Book: On Call Principles and Protocols E-Book | |
| JP2006514053A (en) | Compositions, methods, and kits useful for alleviating gastrointestinal side effects of lipase inhibitors | |
| Asouhidou et al. | Anatomical variation of left internal jugular vein: clinical significance for an anaesthesiologist | |
| CN103202816B (en) | Pantoprazole sodium freeze-dried powder injection | |
| CN102711463B (en) | Hypersulfated disaccharide formulations | |
| CN110327471A (en) | A kind of endoscopy spasmolysis defoaming agent and preparation method thereof | |
| CN107362354A (en) | A kind of oral insulin nanometer formulation and preparation method thereof | |
| WO2024077903A1 (en) | Two-component stomach ultrasonic examination contrast agent and preparation method therefor | |
| CN104666255A (en) | Omeprazole sodium freeze drying powder injection pharmaceutical composition for injection | |
| JPH06321786A (en) | Agent for inhibiting absorption of bile acid in enteric canal | |
| JP2001523241A (en) | Gastric retention pharmaceutical composition | |
| CN103169674A (en) | Omeprazole sodium freeze-dried powder injection for injection | |
| CN110314134A (en) | A kind of gastrointestinal endoscopy auxiliary water and preparation method thereof | |
| CN102917586A (en) | Hypersulfated glucopyranosides | |
| RU2325187C1 (en) | Pharmaceutical formulation of antibiotics and prebiotics (versions) applied for prevention and medical treatment of disbioses caused by antibacterial therapy | |
| JP3177707B2 (en) | Gastrointestinal gas remover | |
| Mohammed et al. | Hypertonic saline for goal-directed therapy guided by Capstesia in gastrointestinal surgery: a randomized controlled study | |
| EP1875928A1 (en) | Novel method of using triacetin and auxiliary agent for ultrasonic diagnostic examination | |
| CN103446594A (en) | Method for preparing medical defoaming agent from simethicone and differential silicone | |
| JP7320903B2 (en) | Compositions and uses containing abiraterone acetate | |
| CN106178137A (en) | A kind of preparation method of medical catheter hydrophilic coating | |
| Uomo | Conservative Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210527 Address after: 100094 No. 4009-14, 4th floor, block B, building 1, yard 2, Yongcheng North Road, Haidian District, Beijing Applicant after: Onas (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: 100102 room 310, 3rd floor, building 605, wangjingyuan, Chaoyang District, Beijing Applicant before: BEIJING GEFEI MEDICAL DEVICES Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231101 Address after: Room 6619, 6th Floor, Building 2, No. 9 Xiaotun Road, Fengtai District, Beijing, 100141 Patentee after: Beijing Yiliya Medical Technology Co.,Ltd. Address before: 100094 No. 4009-14, 4th floor, block B, building 1, yard 2, Yongcheng North Road, Haidian District, Beijing Patentee before: Onas (Beijing) Pharmaceutical Technology Co.,Ltd. |